The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 21, 2025
Filed:
Dec. 17, 2020
Applicant:
Intervet Inc., Madison, NJ (US);
Inventors:
Markus Hendrikus Van Roosmalen, Berkel-Enschot, NL;
Koen Gevers, Boxmeer, NL;
Assignee:
Intervet Inc., Rahway, NJ (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/44 (2006.01); A61K 35/20 (2006.01); A61K 39/00 (2006.01); A61K 39/002 (2006.01); A61K 39/39 (2006.01); A61P 1/12 (2006.01); A61P 33/02 (2006.01); C07K 16/20 (2006.01); C12P 21/02 (2006.01);
U.S. Cl.
CPC ...
C07K 14/44 (2013.01); A61K 35/20 (2013.01); A61K 39/002 (2013.01); A61K 39/39 (2013.01); A61P 1/12 (2018.01); A61P 33/02 (2018.01); C07K 16/20 (2013.01); C12P 21/02 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55511 (2013.01);
Abstract
The invention is based on the finding that incubating a Cryptosporidium gp40 protein with an aziridine, significantly increases its immunogenicity. When used as a vaccine, this allows a reduction of the dose, which improves economic feasibility and safety. Consequently the aziridine-treated gp40 can now be used as a safe and effective subunit-vaccine for humans or non-human-animals against Cryptosporidiosis. Specifically for new-born ruminants a vaccination by way of colostral transfer was found to be very effective in reducing clinical signs of Cryptosporidiosis, especially diarrhoea.